Create New Standards of Care at Daiichi Sankyo’s 2024 Pharma Day® 

May 14, 2024

MassBio is partnering with Daiichi Sankyo on July 16, 2024, to host 2024 Daiichi Sankyo Pharma Day®. MassBio’s Pharma Days are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging their world-class science and technology to enrich the quality of life around the world.

What they’re saying:

“At Daiichi Sankyo, we have a firm commitment to flexibility and transparency for all our alliances in service to making any collaboration greater than the sum of its parts. By creating tailored business models for each asset, we have built a history of strong, successful partnerships in the interest of rapidly bringing innovative therapies to patients. Our oncology pipeline is one of the strongest in the industry with great potential for transforming the way diseases are treated. Our early research team focuses on new approaches to care, leveraging our world-class technology and expertise. Together with our partners, we believe we can transform standards of care.”

– Stu Mackey, Global Head Business Development, Daiichi Sankyo

Hear the latest: Join Daiichi Sankyo’s open information session for the latest insights on its R&D strategy, target therapeutic areas, and partnering capabilities. A networking reception will follow this session.

Get closer: Throughout the day on July 16, companies and researchers affiliated with a university are encouraged to apply for a one-on-one meeting with Daiichi Sankyo representatives. Daiichi Sankyo’s target therapeutic areas are:

  • Earlier stage approaches & platforms, including:
    • Discovery platform for tumor environment-dependent functional peptides
    • Antibodies (including VHH antibodies), peptides, or small molecules with high penetration and retention in tumor stroma
    • New targets for gene therapy
  • Oncology, later stage assets
    • Post-preclinical or clinical-stage oncology programs with the potential to combine with DXd-based ADCs (or topoisomerase I inhibitors) to improve clinical outcomes by broadening the addressable population or increasing the duration of response.
    • Mechanisms of action of interest potentially include some of the following:
      • Cell Cycle regulation
      • TKI (Tyrosine Kinase Inhibitors) in priority indications
      • DDR (DNA Damage Response)
  • Non-oncology, late-stage assets (Phase 2 ongoing or later) Regional Partnerships
  • Non-oncology, research, including psychiatric disorders, cardiovascular, and others

If your company meets our eligibility guidelines, apply for a 1:1 by May 24, 2024 at 11:59 PM ET.

See all MassBio News